Brokerages Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) PT at $5.77

CytomX Therapeutics, Inc. (NASDAQ:CTMX) has been given an average rating of “Moderate Buy” by the six brokerages that are presently covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $5.77.

Separately, HC Wainwright reissued a “neutral” rating on shares of CytomX Therapeutics in a report on Tuesday, January 7th.

CytomX Therapeutics Stock Performance

NASDAQ:CTMX opened at $0.79 on Friday. The firm’s fifty day moving average is $1.01 and its two-hundred day moving average is $1.09. The firm has a market cap of $61.84 million, a price-to-earnings ratio of 4.65 and a beta of 1.01. CytomX Therapeutics has a one year low of $0.78 and a one year high of $5.85.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Monimus Capital Management LP acquired a new position in shares of CytomX Therapeutics during the 4th quarter worth about $375,000. Miller Financial Services LLC purchased a new stake in CytomX Therapeutics during the 4th quarter worth approximately $26,000. Traphagen Investment Advisors LLC acquired a new position in shares of CytomX Therapeutics during the fourth quarter valued at approximately $31,000. Virtu Financial LLC acquired a new position in shares of CytomX Therapeutics during the third quarter valued at approximately $104,000. Finally, Geode Capital Management LLC lifted its position in shares of CytomX Therapeutics by 4.4% in the third quarter. Geode Capital Management LLC now owns 803,531 shares of the biotechnology company’s stock valued at $948,000 after acquiring an additional 34,032 shares in the last quarter. 67.77% of the stock is owned by institutional investors and hedge funds.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.